5:19 PM ET
8-K
Regulatory Approval
ImmunityBio Regulatory Approval
The FDA has expanded the approved indication for ImmunityBio's ANKTIVA in combination with BCG to include patients with BCG-unresponsive NMIBC with papillary-only tumors. This follows the initial April 2024 approval and broadens the addressable patient population to include all patients with BCG-unresponsive NMIBC, a group that represents approximately 85% of the NMIBC population.